^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

NY-ESO-1 TCR-T cell therapy

i
Other names: NY-ESO-1 TCR-T cell therapy, TCR engineered T cell therapy, NY-ESO-1 TCR-T triple knockout TCR therapy, NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1, NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells, NYCE T Cells
Associations
News
Trials
Company:
Gilead
Drug class:
PD1 inhibitor, TCR modulator, NY ESO 1 inhibitor
Related drugs:
Associations
News
Trials